Takeda Pharmaceutical (TAK) said Friday its experimental drug, arcotatug tavatecan, met both primary goals in a phase 3 trial involving certain patients with advanced gastric or gastroesophageal junction cancer.
The company said the study showed that patients receiving the drug lived a median of 10.2 months, compared with 6.9 months for those receiving standard treatment.
Median progression-free survival was 7.1 months versus 3.1 months, respectively, the company said.
Takeda said the drug also achieved a 37.4% response rate, compared with 7.7% for standard treatment.
The company said it plans to use the results to support a regulatory filing in Japan and advance global phase 3 trials in gastric and pancreatic cancer.
Comments